New business models for antibiotic innovation

Upsala Journal of Medical Sciences

Volumn 119, Issue 2, 2014, Pages 176-180

  So, Anthony D ^a   Shah, Tejen A ^a  

^a DUKE UNIVERSITY   (United States)

Author keywords

3Rs strategy; Antibiotic innovation; Antibiotic resistance; Business models; Delinkage

Indexed keywords

ANTIINFECTIVE AGENT;

SYNTHESIS; THEORETICAL MODEL;

ANTI-BACTERIAL AGENTS; MODELS, THEORETICAL;

EID: 84900837864     PISSN: 03009734     EISSN: None     Source Type: Journal    
DOI: 10.3109/03009734.2014.898717     Document Type: Review

References (25)

1. Coates AR, Halls G, Hu Y. Novel classes of antibiotics or more of the same? Br J Pharmacol. 2011;16:184-94.
2. Freire-Moran L, Aronsson B, Manz C, Gyssens IC, So AD, Monnet DL, et al. Critical shortage of new antibiotics in development against multidrug-resistant bacteria-time to react is now. Drug Resist Updat. 2011;14:118-24.
3. Hamad B. The antibiotics market. Nat Rev Drug Discov. 2010;9:675-6.
4. Stewart JJ, Allison PN, Johnson RS. Putting a price on biotechnology. Nat Biotechnol. 2001;19:813-17.
5. Projan SJ. Why is big Pharma getting out of antibacterial drug discovery? Curr Opin Microbiol. 2003;6:427-30.
6. Powers JH. Antimicrobial drug development-the past, the present, and the future. Clin Microbiol Infect. 2004;10: 23-31.
7. Kung HC, Hoyert DL, Xu J, Murphy SL. Deaths: final data for 2005. Natl Vital Stat Rep. 2008;56:1-120.
8. So AD, Gupta N, Brahmachari SK, Chopra I, Munos B, Nathan C, et al. Towards new business models for R&D for novel antibiotics. Drug Resist Updat. 2011;14:88-94.
9. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov. 2006;6:29-40.
10. O'Shea R, Mosser HE. Physicochemical properties of antibacterial compounds: implications for drug discovery. J Med Chem. 2008;51:2871-8.
11. Fernandes P. Antibacterial discovery and development-the failure of success? Nat Biotechnol. 2006;24:1497-503.
12. Di Masi JA. Success rates for new drugs entering clinical testing in the United States. Clin Pharmacol Ther. 1995; 58:1-14.
13. Evans R, Hinds S, Hammock D. Portfolio analysis and R&D decision making. Nat Rev Drug Discov. 2009;8:189-90.
14. US FDA Center for Drug Evaluation and Research. Guidance for industry: acute bacterial skin and skin structure infections: developing drugs for treatment. Washington, DC: US Department of Health and Human Services, Food and Drug Administration; 2010.
15. Outterson K, Powers JH, Seoane-Vasquez E, Rodriguez-Monguio R, Kesselheim AS. Approval and withdrawal of new antibiotics and other antiinfectives in the U.S., 1980- 2009. J Law Med Ethics. 2013;41:688-96.
16. Ross D. The FDA and the case of Ketek. N Engl JMed. 2007; 356:1601-4.
17. Soreth J, Cox E, Kweder S, Jenkins J, Galson S. Ketek-the FDA perspective. N Engl J Med. 2007;356:1675-6.
18. Carome M, Wolfe SM. Public citizen letter to FDA opposing approval of bedaquiline, December 21. 2012. Available at http://www.citizen.org/documents/ 2088.pdf. Accessed on: December 13, 2013
19. Love J, Hubbard T. The big idea: prizes to stimulate R&D for new medicines. Chic Kent Law Rev. 2007;82:1519-50.
20. So AD, Bigdeli M, Tomson G, Woodhouse W, Ombaka E, Peralta AQ. Antibiotic resistance - the need for global solutions. Part 5: the access and excess dilemma (pp. 1071-5). Lancet Infect Dis. 2013;13:1057-98.
21. Critical Path Institute [Internet]. Coalition Against Major Diseases [Internet]. 2013. Available at http://c-path.org/programs/camd/camd-overview/ camd-progress/. Accessed on: December 14, 2013.
22. So AD, Ruiz-Esparza Q, Gupta N, Cars O. 3Rs for innovating novel antibiotics: sharing resources, risks, and rewards. BMJ. 2012;344:e1782.
23. Pelaez F. The historical delivery of antibiotics from microbial natural products-can history repeat? Biochem Pharmacol. 2006;71:981-90.
24. Di Masi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ. 2003;22:151-85.
25. Gupta R, Kim JY, Espinal MA, Caudron JM, Pecoul B, Farmer PE, et al. Responding to market failures in tuberculosis control. Science. 2001;293:1049-51.